News & Events

• September 1, 2018
  

  Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis

  Rancoita PMV, Cugnata F, Gibertoni Cruz AL, Borroni E, Hoosdally SJ, Walker TM, et al. Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2018 Sep;62(9).

• June 1, 2018
  

  Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study

  Zignol M, Cabibbe AM, Dean AS, Glaziou P, Alikhanova N, Ama C, et al. Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study. Lancet Infect Dis. 2018 Jun;18(6):675–83.

• June 1, 2018
  

  Mycobacterial biomaterials and resources for researchers

  Hazbón MH, Rigouts L, Schito M, Ezewudo M, Kudo T, Itoh T, et al. Mycobacterial biomaterials and resources for researchers. Pathog Dis. 2018 Jun 1;76(4).

• March 14, 2018
  

  Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin

  Patel N, Hatley O, Berg A, Romero K, Wisniowska B, Hanna D, et al. Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin. AAPS J. 2018 May 1;20(3):47.

• March 8, 2018
  

  Quantitative Approach for Cardiac Risk Assessment and Interpretation in Tuberculosis Drug Development

  Polak S, Romero K, Berg A, Patel N, Jamei M, Hermann D, et al. Quantitative approach for cardiac risk assessment and interpretation in tuberculosis drug development. J Pharmacokinet Pharmacodyn. 2018 Mar 8;1–11.